Xcellerex is a developer and producer of turn-key bio-manufacturing systems and production-scale bioreactors based around single-use components. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bioproducts, such as vaccines, yeast, and insulins.
Financial terms were not disclosed. The acquisition is expected to close in the second quarter of 2012.
Xcellerex, based in Marlborough, Mass., employs approximately 135 people and had revenues of approximately $50 million in 2011.
Related Articles on Company Acquisitions:
ZOLL Medical to be Acquired by Tokyo’s Asahi Kasei for $2.2B
Boston Scientific to Acquire Cameron Health
Nuance to Acquire Medical Transcription Company Transcend Services for $300M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.